Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gram-negative bacterial iron transport proteins, primarily TonB-dependent receptors (TBDRs), are essential outer membrane transporters that facilitate the uptake of iron-siderophore complexes (Noinaj et al., 2010, Nature Reviews Microbiology). Since iron is a critical micronutrient for bacterial survival and virulence, these proteins are vital for establishing infections in the host (Cornelis, 2010, Natural Product Reports). These transporters are exploited by Trojan horse antibiotics, such as cefiderocol, which mimic siderophores to gain entry into the bacterial periplasm, bypassing traditional resistance mechanisms like porin loss (Zhanel et al., 2019, Drugs). The TonB-ExbB-ExbD complex provides the necessary energy for this active transport process across the outer membrane (Postle & Kadner, 2003, Annual Review of Microbiology). Targeting these systems is a key strategy for addressing multi-drug resistant (MDR) pathogens like Acinetobacter baumannii and Pseudomonas aeruginosa (Page, 2019, Annals of the New York Academy of Sciences). These proteins are highly regulated by the Ferric Uptake Regulator (Fur) protein, which ensures their expression is upregulated under iron-limited conditions typical of the human host (Fillat, 2014, BioMetals). Therapeutic interventions targeting these proteins include both direct inhibition of transport and the use of siderophore-drug conjugates to deliver bactericidal payloads (Krewulak & Vogel, 2008, Biochimica et Biophysica Acta).
Siderophore-mediated active transport (Trojan horse mechanism) where the drug mimics a siderophore to gain entry into the bacterial cell via iron transporters (Zhanel et al., 2019, Drugs).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gram-negative bacterial iron transport protein (TBDR).